Report Overview

The global osteoporosis drugs market size stood at USD 13.5 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

The major factor that contributes to the growth of osteoporosis drugs market include rise in prevalence of osteoporosis. Furthermore, other factors that boost the growth of the osteoporosis drug market are a surge in the geriatric population across the globe and a rise in the adoption of sedentary lifestyles worldwide. However, the side effects of osteoporosis drugs and the time-consuming drug approval process hamper the growth of the osteoporosis drug market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period



Market Growth Drivers

Rising expenditure in the discovery and development of drugs to treat osteoporosis is also a major factor driving the growth of the osteoporosis drug market. The rapid pace of urbanization giving rise to unhealthy lifestyle and eating habits, which are expected to lead to a greater number of people being impacted by this disease, thereby driving the growth of the osteoporosis drug market. Rising demand for better osteoporotic care, coupled with increasing awareness about the availability of drugs for treating the disease, is pushing market players to work in the drug development area for this indication. The market players are collaborating with patient organizations, government research organizations, and academic institutes to advance their drug development activities. All these factors are expected to drive market growth in the coming years